Adicet Bio (ACET)

• Market cap: $75.4M
• 1 day: -5.37%
• 5 days: 0.43%
• 1 month: -19.37%
• 3 months: -40.77%
• 6 months: -19.33%
• Year to date: -49.47%
• 1 year: -45.36%
• 5 years: -96.4%
• 10 years: -99.58%
• Sector: Healthcare
• Industry: Biotechnology

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 152